Thursday, October 25, 2012

AstraZeneca CEO: Expect to Update on Strategy End-January 2013 | Fox Business

via foxbusiness.com

AstraZeneca PLC's (AZN) new chief executive, Pascal Soriot, said Thursday he expects to be in a position to update investors on his strategy to revive the drug maker's fortunes from late January at the earliest.
On a conference call with reporters, Dr. Soriot, who started his job earlier this month, said he wanted to take as much time as he needed to complete a review of the business before making any decisions, and had been meeting investors and staff as he considered the options for the troubled company.
AstraZeneca said earlier that third-quarter net profit fell by more than 50%, due to a sharp decline in revenue driven primarily by the loss of patent protection on its antischizophrenia drug Seroquel IR.

Read more: http://www.foxbusiness.com/news/2012/10/25/astrazeneca-ceo-expect-to-update-o...?#ixzz2AIy3Mr41

Posted via email from Jack's posterous

No comments: